Link to study page:

https://www.ncbi.nlm.nih.gov/pubmed/31916890?fbclid=IwAR22XC8-o10mbJZo3Pnyv1x6S4Wm3RamhT9wsI9KgOw_owm37lflNugcUoE

RESULTS:

Reductions in anxiety, depression, hopelessness, demoralization, and death anxiety were sustained at the first and second follow-ups. Within-group effect sizes were large. At the second (4.5 year) follow-up approximately 60-80% of participants met criteria for clinically significant antidepressant or anxiolytic responses. Participants overwhelmingly (71-100%) attributed positive life changes to the psilocybin-assisted therapy experience and rated it among the most personally meaningful and spiritually significant experiences of their lives.